Back to Trial

Oracle Runs

Oracle findings and outcome history for A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment (NCT06105632).

Runs
1
Findings
1
Latest Run
Apr 1, 2026, 6:34 PM
Resolution Evidence
Outcome
YES
Status
Resolved
Settlement Date
4/1/26 UTC
Executive Summary

This exact Phase 2 trial (FOURLIGHT-1; NCT06105632) has already had a public readout. Pfizer explicitly called the topline results positive, said the study met its primary endpoint, and described the PFS benefit as statistically significant and clinically meaningful for this trial.

Sources
Sponsorpfizer.com3/17/26
Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Pfizer said FOURLIGHT-1 was positive: the study met its primary endpoint and showed a statistically significant, clinically meaningful PFS improvement for atirmociclib + fulvestrant.

View source
ClinicalTrialsclinicaltrials.gov
Study Details | NCT06105632 | ClinicalTrials.gov

ClinicalTrials.gov identifies NCT06105632 as FOURLIGHT-1, a Phase 2 study of PF-07220060 plus fulvestrant versus physician’s choice in HR+/HER2- advanced or metastatic breast cancer.

View source
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

YESAccepted98% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

This exact Phase 2 trial (FOURLIGHT-1; NCT06105632) has already had a public readout. Pfizer explicitly called the topline results positive, said the study met its primary endpoint, and described the PFS benefit as statistically significant and clinically meaningful for this trial.

Found Apr 1, 2026, 6:34 PMOutcome date Mar 17, 2026, 1:45 PMReviewed Apr 1, 2026, 6:36 PM
Sponsorpfizer.comMar 17, 2026, 1:45 PM
Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer
Pfizer said FOURLIGHT-1 was positive: the study met its primary endpoint and showed a statistically significant, clinically meaningful PFS improvement for atirmociclib + fulvestrant.
ClinicalTrialsclinicaltrials.gov
Study Details | NCT06105632 | ClinicalTrials.gov
ClinicalTrials.gov identifies NCT06105632 as FOURLIGHT-1, a Phase 2 study of PF-07220060 plus fulvestrant versus physician’s choice in HR+/HER2- advanced or metastatic breast cancer.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

Accepted Oracle Review (Legacy)Apr 1, 2026, 6:36 PM

Will the results be positive?

PendingtoYEScurrentYES
GPT-5.4 (OpenAI)98% confidenceReviewed Apr 1, 2026, 6:36 PM

This exact Phase 2 trial (FOURLIGHT-1; NCT06105632) has already had a public readout. Pfizer explicitly called the topline results positive, said the study met its primary endpoint, and described the PFS benefit as statistically significant and clinically meaningful for this trial.